A diagnosis of motor Parkinson’s disease (PD) is preceded by a prolonged premotor phase with accumulating neuronal damage. Here we examined the temporal relation between α-synuclein (α-syn) T cell reactivity and PD. A longitudinal case study revealed that elevated α-syn-specific T cell responses were detected prior to the diagnosis of motor PD, and declined after. The relationship between T cell reactivity and early PD in two independent cohorts showed that α-syn-specific T cell responses were highest shortly after diagnosis of motor PD and then decreased. Additional analysis revealed significant association of α-syn-specific T cell responses with age and lower levodopa equivalent dose. These results confirm the presence of α-syn-reactive T cells in PD and show that they are most abundant immediately after diagnosis of motor PD. These cells may be present years before the diagnosis of motor PD, suggesting avenues of investigation into PD pathogenesis and potential early diagnosis.
Parkinson’s disease (PD) is a complex disease with several phases: a preclinical phase that may include physiological or pathological changes, but no symptoms; a prodromal phase that includes non-motor symptoms such as constipation, REM sleep behavior disorder, and hyposmia1; and motor PD characterized by the cardinal features of tremor, rigidity, bradykinesia, and postural imbalance. The presence of these motor features allows clinical diagnosis of PD.
The motor symptoms of PD are primarily due to the loss of dopaminergic neurons of the substantia nigra pars reticulata (SNpc)2. In postmortem brain, loss of dopaminergic neurons can be detected by stereological analysis and labeling of the dopamine synthetic enzyme tyrosine hydroxylase3. A stereological analysis of 20 brains from subjects who died from 1 to 27 years after PD diagnosis indicates that the number of SNpc neurons is decreased by 50–90% during the first four years following diagnosis3; while after this period, the number of labeled neurons remains fairly constant. Similarly, the number of neuromelanin-pigmented SNpc cells from the same subjects at 3 to 7 years post diagnosis shows a decrease of 33–80% relative to controls. By 4 years after diagnosis of motor PD, the markers of dopamine axons in the dorsal putamen are virtually absent. These observations are consistent with a premotor phase during which there is extensive damage to SNpc neurons preceding the motor symptoms that typically lead to diagnosis and the identification of clinical disease1.
The concept of an extensive prodromal phase of PD is further supported by the very common occurrence of symptoms that precede the diagnosis of motor PD, including hyposmia, constipation, mood changes, and REM sleep behavior disorder1. Although these symptoms can precede PD diagnosis by decades, their presence is not sufficient to diagnose PD and, although sensitivity is relatively good, the specificity is poor for most subjects4. These prodromal non-motor features often associated with PD are thought to be due to the loss of additional catecholaminergic and cholinergic neurons and other pathological changes outside the SNpc5.
Attempts to develop treatment to slow the progression of PD have so far been unsuccessful. One of the important factors in the lack of success is that it may be difficult to modify the disease when treatment is initiated after the majority of SNpc neurons have already been lost. Thus, identifying effective early predictors of PD is of fundamental importance to developing future therapies6. One approach to develop early prediction is to identify additional features associated with the preclinical or prodromal phases of PD, including potential inflammatory manifestations7,8.
A recent study by our team found that some PD patients possess T cells that recognize specific epitopes derived from the PD-associated protein, α-synuclein (α-syn)9, indicating the presence of autoimmune features in this disease. Classical autoimmune disorders such as diabetes mellitus type I are well established to display differences in specific T cell types over the course of the disease10. Here, we present an analysis of α-syn-specific T cells in two ways: (1) by examining a case study of a single individual with blood samples from many years prior to and during the course of motor PD, and (2) by investigating α-syn-specific T cells in two cohorts of PD patients and age-matched non-PD controls. We detected α-syn-specific T cells in the single case years before clinical diagnosis of motor PD, and a higher abundance of pro-inflammatory T cells in a cross-sectional PD patient population shortly after diagnosis of motor PD. These findings indicate that specific T cell reactivity to α-syn-derived epitopes is a feature of premotor and early motor PD.
A case study of α-syn-specific T cell reactivity
We were contacted by an individual who was diagnosed with motor PD in 2009 but was otherwise healthy, and who had for unrelated reasons cryopreserved peripheral blood mononuclear cell (PBMC) samples available that were collected from 1998 to present. The individual had read our previous study9 and generously donated the previously collected samples for analysis. As in the previous study, PBMCs were stimulated for 14 days in vitro with an α-syn epitope pool (a total of 12 peptides). After 2 weeks, cultures were harvested and stimulated with antigen or PHA, as a control, in a triple-color IFNγ, IL-5, and IL-10 Fluorospot assay. As before, IFNγ was examined as a representative cytokine for CD4+ Th1 cells and CD8+ T cells, while IL-5/IL-4 (in flow cytometry assays) was examined to indicate CD4+ Th2 T cells, and, in addition, IL-10 was analyzed as representative of potential regulatory cells.
We detected α-syn-specific T cell reactivity that was deconvoluted and mapped to the α-syn61-75EQVTNVGGAVVTGVT peptide in samples from 2005, 2006, and 2015 (Fig. 1a and Supplementary Fig. 1). Since we had access to the HLA type of the donor, we were able to predict HLA binding of this particular peptide to each of the expressed alleles. The EQVTNVGGAVVTGVT peptide was predicted to bind with high affinity (71 nM) to the HLA DRB1*01:01 allele expressed by the donor (HLA type of case study donor: DRB1*01:01/*03:01, DRB3*01:01, DQB1*02:01/*05:01, DQA1*01:01/*05:01; DPB1*04:01/*04:01). The α-syn-specific response was further characterized by ICS assays in samples collected between 1998 and 2015, which revealed that the response was mediated by CD4+ T cells for both IFNγ and IL-4 (Fig. 1b, c). No α-syn-specific IL-10 production was detected in the ICS assay (Fig. 1d).
We then analyzed the evolution of the α-syn-specific and globally stimulated (PHA control) T cell reactivity. Notably, strong T cell reactivity against α-syn was detected between the years 1998 and 2006, more than a decade before the onset of motor PD symptoms and clinical diagnosis. No samples were analyzed for reactivity between the onset of motor PD symptoms and clinical diagnosis. Significant variability in α-syn-specific responses was observed between 2006 and 2008, including in the positive PHA controls, during which the donor experienced shingles (herpes zoster). Interestingly, the α-syn-specific reactivity detected after diagnosis (2012–2018) was significantly lower than between 1998 and 2006 (Fig. 1e). Overall, there was a significant difference in α-syn-specific T cell reactivity comparing pre- and post-PD onset/diagnosis, while no significant difference was observed for the PHA control (Fig. 1f).
Taken together, this case study revealed strong CD4+ T cell responses against the EQVTNVGGAVVTGVT α-syn epitope. The reactivity was detectable 10 years before onset and diagnosis of motor PD, and was associated with a wide variation in response magnitude. Higher responses were detected before onset/diagnosis, leading us to design a broader study of T cell responses over the course of PD.
Preferential α-syn-specific T cell reactivity in PD
Previously reported α-syn-specific T cell reactivity was determined in a cohort of individuals recruited by the Columbia University Medical Center (CUMC) and the La Jolla Institute for Immunology (LJI). Here, we enrolled additional donors from RUMC, UCSD, and University of Alabama at Birmingham (UAB) (see “Material and methods”). We determined the α-syn-specific T cell reactivity in PD patients and healthy age-matched controls (HC) from these sites. As before, PBMCs were stimulated for 14 days with an α-syn epitope pool derived from the previous study9, and IFNγ, IL-5, and IL-10 responses against the epitope pool were measured in IFNγ, IL-5, and IL-10 Fluorospot assays after the in vitro culture. If cell numbers allowed, positive pools were deconvoluted to identify the specific peptides that elicited cytokine responses. We previously reported higher α-syn-specific reactivity in PD compared with HC, when comparing the magnitude of response against peptide and participant combinations9. The present results in this heterogenous population against the 11 different epitopes deconvoluted after in vitro stimulation confirmed significantly higher magnitude of responses in PD than HC (p < 0.0001, Supplementary Fig. 2).
Subsequent analysis focused on responses to the peptide pool with 11 α-syn-derived epitopes; deconvolution of all peptides could not be consistently performed due to limited cell numbers. Comparison of IFNγ, IL-5, and IL-10 production between the two cohorts on a per donor basis revealed no differences when IL-5 and IFNγ were considered separately (Fig. 2a, b), and a significant difference when the IL-10 responses were considered (p = 0.04, Fig. 2c). When the overall sum of responses was compared between PD and HC, there were significantly higher overall responses when an arbitrary threshold of 250 SFC was considered (p = 0.02; Fisher’s exact test, Fig. 2d).
To determine whether the higher α-syn-specific T cell responses in individuals with PD compared with HC occurs in other neurodegenerative diseases, we determined the α-syn-specific T cell reactivity in Alzheimer’s disease (AD) patients and HC (Materials and methods). There was no difference in reactivity between these cohorts (p = 0.15; two-tailed Mann–Whitney test, and p = 0.21; Fisher’s exact test with a threshold of 250 SFC, Fig. 2e). We further compared the HC from the PD study to the HC from the AD study, as well as the PD and AD cohorts. No differences were observed by the Fisher’s exact test at a threshold of 250 SFC (p = 0.102 for HC in PD vs. HC in AD, and p = 0.196 for PD vs. AD).
T cell reactivity is associated with early time points
To gain further insight into the relation between disease pathogenesis and T cell reactivity, we examined whether the T cell response in a cross-sectional cohort was correlated with time from diagnosis of motor PD. We found that the reactivity was higher closer to PD diagnosis and then waned (Fig. 3a).
To confirm the inverse correlation between time from diagnosis and α-syn-specific reactivity, samples derived from a new independent cohort of 20 PD patients, all recruited within 10 years of diagnosis, were analyzed. The results shown in Fig. 3b confirm the previous finding of the reactivity being higher closer to PD diagnosis.
When all the data were considered and plotted together (Fig. 3c), the higher reactivity closer to PD diagnosis was evident. Overall when the frequency of PD patients responding above an arbitrary cut-off of 250 SFC was considered, 39.7% (29/73) of donors diagnosed <10 years ago responded, whereas only 8.6% of donors (3/23) with diagnosis >10 years ago exhibited a response to α-syn (p = 0.022, Table 1).
T cell reactivity is linked to pro-inflammatory cytokines
Next, we investigated in more detail the relationship between time since diagnosis and IFNγ, IL-5, and IL-10 production. We found that the trend for all cytokines was the same, with the reactivity being higher closer to diagnosis (Fig. 4a–c).
We also calculated the frequency of response using the same cut-offs as above: 250 SFC and 10 years of diagnosis (Table 1). We found that, in the case of IFNγ, 26% (19/73) of patients diagnosed <10 years ago responded as compared with 4.3% (1/23) diagnosed >10 years ago (p = 0.036). In the case of IL-5 and IL-10, 15% (11/73) and 16.4% (12/73) of patients diagnosed <10 years ago responded, respectively, while only 4.3% (1/23) of those diagnosed >10 years ago responded, which corresponded to a nonsignificant trend (p = 0.283 and 0.179) in the same direction as observed for IFNγ. Overall, these data indicate a negative (inverse) correlation between the number of years after disease onset and T cell reactivity.
In our previous study9, although IL-10 production was not investigated in detail, the limited analysis we did indicated that most of the α-syn-specific responses were mediated by CD4+ T cells with one CD8/class I restricted epitope also identified. Here, to address the cell type associated with IL-10 production, 20 PD donors were stimulated in vitro with an α-syn epitope pool for 2 weeks, and then the production of IFNγ, IL-4, and IL-10 along with the lineage-specific markers CD56, CD19, CD14, CD3, CD4, and CD8 was analyzed by flow cytometry. The results indicated that IFNγ and IL-4 were produced primarily by CD4+ T cells, while IL-10 is produced by both CD4+ and CD8+ T cells (Fig. 5a–c), consistent with the previously reported data9. Boolean gating of cytokine responses revealed that the majority of responses were from unique T cells producing one of the three cytokines, IFNγ, IL-4, or IL-10 (Fig. 5d), although some cells produced both IFNγ and IL-4.
Because of their potential role in downregulating immune responses, the phenotype of IL-10-producing T cells was examined in more detail with particular attention to whether they expressed markers associated with regulatory T cell (Treg) populations, and conversely, whether Treg populations stimulated with α-syn epitopes secreted IL-10. For this purpose, cells were stained with CD3, CD4, CD8, CD127, and CD25 along with IFNγ, IL-4, and IL-10 after 2-week in vitro stimulation assay. The results demonstrated that IL-10 production was not associated with expression of CD25+CD127lo Tregs, and conversely, that CD25+CD127lo-expressing Tregs do not produce IL-10 in response to the α-syn epitopes (Fig. 5e). Thus, a population of CD25−CD127− T cells was responsible for the α-syn-specific IL-10 response detected.
LED and age correlate with α-syn-specific T cell reactivity
We next examined if the α-syn-specific T cell reactivity correlated with clinical and patient-specific characteristics other than time since diagnosis. We evaluated correlations of α-syn-specific T cell reactivity with patient age, sex, and HLA type, as well as with measurements of PD severity such as cognitive function (the Montreal Cognitive Assessment (MoCA)11), motor examination (Part III from the Unified Parkinson’s Disease Rating Scale (UPDRS)12), and medication (levodopa equivalent dose; LED13) scores. We found a positive correlation between age and T cell reactivity to α-syn, with patients older than 70 years having more frequent responses (p = 0.0177 Fisher’s exact test, Fig. 6a). No correlations between age and T cell reactivity to α-syn were found in HC (p = 0.51, Supplementary Fig. 3). We also noted a trend toward correlation between T cell responses and sex (Fig. 6b). Only 6 out of 26 (23%) female PD patients tested responded to α-syn, as opposed to 27 out of 71 (38%) male patients, although this difference was not significant (p = 0.2279, with male donors showing a trend toward responding more vigorously than female donors). These results are consistent with an overall increase of autoimmunity with age14.
Our previous publication found an association with α-syn-specific Y39 T cell responses and HLA DRB1*15:01 and DRB5*01:019. Here, we compared the HLA alleles expressed by PD patients to those expressed by HC to find HLA associations of PD. We found that no HLA allele was associated with PD disease after Bonferroni correction for multiple comparisons (Supplementary Table 1). We also compared the HLA alleles of α-syn responding individuals (either PD or HC with SFC > 250) to nonresponders and found that no significant associations were detected with α-syn responses (Supplementary Table 1).
We next examined potential correlations between T cell reactivity and clinical variables by analyzing the scores for MoCA, which measures cognitive dysfunction; UPDRS, which measures motor and non-motor symptoms and follows the longitudinal progress of PD; and LED, which is designed to quantify anti-Parkinsonian medications. No significant correlation was detected between T cell reactivity and cognitive or motor scores, as MoCA (Fig. 6c) and UPDRS Part III (Fig. 6d) scores were not associated with responses against α-syn. We obtained the complete UPDRS scores (Parts I–IV) available from the cohort recruited at UCSD (n = 33) and none of the subscales of UPDRS were associated with responses against α-syn (Supplementary Fig. 4). No association analysis was performed for Hoehn & Yahr stages because 85% of the PD subjects were Stage 2, and only two individuals were rated as Stage 1 and a single subject was rated as Stage 0, or for the Schwab and England Activities of Daily Living scale, because 94% of the PD subjects scored 80–100%. In contrast, our analyses revealed a significant correlation between low LED (<1000 mg/day) and T cell responses against α-syn (Fig. 6e). We reasoned that low LED levels might be simply correlated with early motor disease. Indeed, we found that, as expected, time from diagnosis and low LED were positively correlated (Spearman r = 0.335, p = 0.0016) (Fig. 6f). We next addressed whether these variables (low LED and time from diagnosis) were independently correlated with α-syn T cell reactivity. For this purpose, we segregated donors as a function of these two variables. We found that responses were essentially limited to donors that had both recent diagnosis and low LED (Fig. 6g). A total of 25/28 responders (SFC > 250) were diagnosed <10 years ago and had a LED score <1000 mg/day, while 33/58 (SFC < 250) did not fit those criteria (p = 0.0029 Fisher’s exact test).
After noting the positive correlation between age and α-syn responses, we found that a combination of low LED (<1000 mg/day), time since diagnosis (<10 years), and age (≥70 years) formed an optimum triad of parameters exhibiting maximum sensitivity and specificity. Of the 22 PD donors that meet these three criteria, 15 responded to α-syn, resulting in 68% specificity (Fig. 6h). This particular combination of the three clinical variables: low LED (<1000 mg/day), time since diagnosis (<10 years), and age (≥70 years), captures 15 out of the 28 total PD donors that responded to α-syn, indicating a 54% sensitivity (Fisher’s exact p = 0.0001, Fig. 6h).
Here we report that, in patients with motor PD, α-syn-specific T cell responses are highest close to the time of motor PD diagnosis and decline thereafter. These T cell responses are associated with diverse immunological phenotypes, including both inflammatory and potentially regulatory cytokine-secreting cells. We demonstrate in a case study of a single individual in which T cells could be analyzed over a decade that this α-syn-specific inflammatory T cell response was present prior to onset of motor symptoms and PD diagnosis. Among the PD cohorts studied after clinical diagnosis of motor PD, we further show that T cell reactivity was positively correlated with age and inversely correlated with LED, but did not correlate with motor and cognitive impairment.
The case study of an individual for which PBMC samples were independently obtained and stored over a 20-year period both before and after clinical diagnosis of motor PD provides a unique opportunity to examine PD disease progression. We found that α-syn-specific T cell reactivity was present before onset of motor symptoms and clinical diagnosis of PD and then declined after. The observation that α-syn reactivity was present during the preclinical phase is compatible with a causal relationship between T cell-mediated inflammation and PD disease. Replication of these findings in larger population-based longitudinal studies will be important, but such cohorts are currently not available. Notably, the case study subject reported having shingles ~1–2 years before PD diagnosis, and we detected a wide variation in α-syn-specific T cell reactivity in samples during that period. It is unclear whether these variations may be due to variations in sample quality and/or the limited number of cells, which did not allow a repeat of the assay multiple times as for other time points. The variation may also be explained by the shingles episode affecting the α-syn-specific T cell responses. This observation is intriguing in the context of a putative role of viral infections in PD pathogenesis15,16. We speculate that the variability in T cell reactivity may have initiated spreading of inflammation and immune responses in the brain that later could not be controlled.
Prompted by these observations, we examined the relation between time from diagnosis of motor PD and α-syn-specific T cell reactivity in two independent cohorts of PD patients and found a significant relationship between time from diagnosis and reactivity. The correlation between α-syn-specific T cell reactivity and time from diagnosis also suggests a pathogenic role of T cell reactivity, but it will be important to examine this further in preclinical and prodromal cohorts, as the mechanism is currently not understood. There is a potential for epitope spreading to occur over time. Due to the limited number of cells, we were unable to identify individual epitopes in all subjects. The limited data in the case study suggests that there was no epitope spreading, as the epitope specificity remained constant between 2005 and 2015.
The studies in these cohorts also suggested a role for cytokine-producing α-syn-specific T cells in PD progression. It is well known that T cells are very heterogeneous17, with different subsets functionally distinguished on the basis of differential cytokine secretion. While IFNγ and IL-4/5 secretion are associated with typical inflammatory Th1/Th1* and Th2 subsets18, other cytokines such as IL-10 that have anti-inflammatory activity are associated with several different subsets, including Tregs, Tr1, and others19.
In this study, we compared α-syn-specific T cell responses between PD patients and age-matched HC. One limitation to this study is that, while the sample size is relatively large, the PD patients and HC were unbalanced for sex. No difference in α-syn-specific T cell reactivity was found between individuals diagnosed with AD and age-matched HC. Comparison of α-syn-specific T cell reactivity to additional neurodegenerative diseases will reveal whether the reactivity is a marker of neuronal loss and associated neuroinflammation that may occur in multiple neurodegenerative diseases, rather than being specific to PD.
Here, we measured classical inflammatory cytokines as well as IL-10. Significant amounts of IL-10 were produced in addition to IFNγ and IL-5. The IL-10 production suggests the possibility that these cells correspond to a compensatory and regulatory subset. Our limited analysis to date indicates that they are T cells that do not express typical markers of the Treg lineage and are distinct from those producing inflammatory cytokines. These cells might correspond to a specific T cell subset that can be characterized further in future studies. Their isolation and characterization could pave the way for active or passive immunotherapy of PD20,21,22.
We also examined the correlation between the presence of different HLA types and PD status (comparing PD with non-PD controls) and in parallel examined the correlation between HLA type and α-syn-specific reactivity in both HC and PD. No significant association was detected when Bonferroni corrections were applied. Thus, the current analysis does not confirm the previous trend (not Bonferroni corrected) for an association with HLA DRB1*15:01 and DRB5*01:019. It should be noted that the previous analysis was performed with a specific DRB1*15:01/DRB5*01:01 restricted epitope, whereas here we studied a pool of 11 α-syn epitopes. In addition, the previous analysis was performed with subjects essentially from a single site, while the present analysis included a more diverse geographical and ethnic basis (New York, Chicago, San Diego, and Birmingham). We also did not find any significant HLA association (Bonferroni corrected) when the individuals from all sites (previous analysis and the current cohorts) were analyzed together. In addition, we did not detect a significant association with the “shared haplotype” recently reported in association with PD23. The present study included a total of 164 subjects and was therefore associated with higher statistical power. We conclude that the issue of HLA association with PD should be addressed in further studies with a larger number of subjects analyzed. We are also currently in the process of coupling HLA association studies with TCR repertoire analyses.
Having established a correlation with time since diagnosis, we focused on additional variables of clinical significance. We detected a trend for association of T cell responses and sex, consistent with the bias of disease occurrence in males24. We also detected a correlation with reactivity and age, with responses tending to increase with age in the individuals with PD, but not the HC. It is important to emphasize that the α-syn-specific reactivity decreases as a function of time from diagnosis but increases as a function of age. This observation excludes a general reduction in reactivity due to aging and is more compatible with a general increase in propensity to autoimmunity with increased age as has been previously described14,25. Surprisingly, we did not detect significant correlation or association with cognitive function (MoCA) or motor (UPDRS) scores. We propose that this might be reflective of the T cell reactivity largely preceding the clinical stage as in classical autoimmune diseases26,27,28, and of T cell reactivity mediating the damage, which does not correlate with disease severity that appears after most of the damage has occurred.
Our analysis detected a strong correlation with low LED (medication scores), and that, while time from diagnosis is as expected correlated with low LED, the two variables also act synergistically. While patients with both low LED and a recent diagnosis exhibit high α-syn-specific reactivity, patients with low LED/distant diagnosis or high LED/recent diagnosis do not show the same high reactivity. This explanation is puzzling, and might relate to high LED/recent diagnosis as a different disease phenotype, with accelerated pathogenesis requiring more medication, or donors where time since diagnosis does not accurately reflect disease onset. One caveat to this study is the risk of potential misdiagnosis of PD in early disease; our PD cohorts were enrolled by fellowship-trained movement disorder specialists and previous studies have shown that the rate of incorrect diagnosis in early PD is around 15%29,30. This could also be addressed in a future longitudinal study.
By combining the three variables (age, LED, and time from diagnosis), we achieved the best classification of PD α-syn responders, with almost 70% specificity but low (54%) sensitivity, perhaps because the reactivity of additional antigens in addition to α-syn might be involved in PD pathogenesis. This is consistent with recent reports of reactivity against tau, β-synuclein, and hypocretin31,32,33. The sensitivity could likely be improved by including additional antigens involved in PD pathogenesis, as well as by narrowing the window of time since onset of disease for a diagnostic application. In terms of specificity, it is possible that some of the age-matched controls will eventually develop PD, considering that reactivity in the case study was detected long before diagnosis.
In conclusion, the present study confirms an association of α-syn-specific T cells and PD, and demonstrates that the presence of these T cells is a feature of preclinical and early motor PD. These observations also suggest that the monitoring α-syn-specific T cell reactivity of at-risk populations, such as REM sleep behavior disorder patients and LRRK2 or GBA carriers, might provide a strategy to identify individuals for preventive treatments and immunotherapy approaches. The feasibility of such an approach is reinforced by a recent report that patients undergoing anti-TNF treatments are associated with lower incidence of PD34.
All participants provided written informed consent for participation in the study. In the case of the AD cohort, all the participants or their authorized representatives provided written informed consent. Ethical approval was obtained from the institutional review boards at La Jolla Institute for Immunology (LJI; Protocol Nos VD-167, VD-124, VD-118, VD-155, and VD-187), Rush University Medical Center (RUMC; Office of Research Affairs No. 16042107-IRB01), University of California San Diego (UCSD; Protocol No. 161224), University of Alabama (UAB; Protocol No. IRB-300001297) and Columbia University Medical Center (CUMC; Protocol No. IRB-AAAQ9714).
Study subjects' PD and age-matched HC
We recruited a total of 97 participants with PD and 67 age-matched healthy controls without PD from the greater San Diego (PD, n = 44; 11 LJI, 33 UCSD; HC, n = 35 from UCSD), Chicago (PD, n = 31; HC, n = 32), and Birmingham, Alabama (PD, n = 22, where 20 were used as an independent validation cohort; HC, n = 0) areas; cross-sectional cohort characteristics are shown in Table 2. Blood samples were collected by trained staff. The San Diego cohort was recruited by the clinical core at LJI and by the Department of Neurology at UCSD. The Alabama cohort was recruited from the clinical practice of the UAB Movement Disorders Clinic and the Chicago cohort was recruited from the Rush Parkinson’s Disease and Movement Disorders Program. PD participants were enrolled on the basis of the following inclusion criteria: moderate to advanced PD; 2 of: rest tremor, rigidity, and/or bradykinesia, PD diagnosis at age 45–75, dopaminergic medication benefit, and ability to provide informed consent, by fellowship-trained movement disorder specialists. Early diagnosis was defined as <10 years prior to sample donation. The exclusion criteria were atypical parkinsonism or other neurological disorders, history of cancer within the past 3 years (not skin), autoimmune disease (except thyroid), and chronic immune-modulatory therapy. Age-matched HC were selected on the basis of age 48–90 and ability to provide informed consent. Exclusion criteria were the same as for PD donors, and, in addition, we excluded self-reported genetic factors (i.e., PD in first-degree blood relative). In the LJI cohort, PD was self-reported. The PD individuals recruited at RUMC, UAB, and UCSD all fulfilled the UK Parkinson’s Disease Society Brain Bank criteria for PD. For the PD patients, the median age at diagnosis was 58 years.
The case study experienced onset of symptoms in 2008 and was diagnosed with PD in 2009 when he was 47 years old. He had an episode of shingles in 2007. Upon diagnosis, the case study, a right-hand-dominated man, presented with a year's history of tremors involving the left arm. He also complained of a sore feeling in the arm and some problems while running involving his left leg. There was a family history of essential tremor, but no history of sleeping problems. He denied having constipation or anosmia, and there was no micrographia. Examination revealed a healthy-appearing male who was cognitively intact (mini-mental state examination (MMSE)—30). He had classic intermittent resting tremor involving the left arm, mild to moderate left arm rigidity, and mild slowing of finger tapping on the left. He had diminished left arm swing, but gait was otherwise normal with a UPDRS motor score of 9. He had a Hoehn & Yahr score Stage 1. He started rasagaline 1 month after first the evaluation in 2009. He started Levodopa in December 2015 and had implantation of bilateral subthalamic stimulators in June 2017 due to intractable tremors. Cryopreserved PBMCs derived from either whole blood or leukapheresis donations, isolated using Ficoll-PaqueTM density-gradient centrifugation as below, were provided from various time points between 1998 and 2018.
Study subjects' AD and age-matched HC
We recruited a total of 38 participants with AD and 41 age-matched healthy controls without AD from the Alzheimer’s Disease Research Center at CUMC (AD, n = 20; HC, n = 21) and Precision Med a Contract Research Organization (AD, n = 18; HC, n = 20). Demographic characteristics of AD and matched HC are listed in Table 3. Blood samples were collected by trained staff.
Subjects from CUMC were diagnosed by neurologists according to the National Institute of Aging and Alzheimer’s Association criteria35. All AD subjects were probable AD, recruited after at least two clinical visits. Ten AD individuals had neuropsychological testing only; the remaining 10 had neuropsychological testing and positive biomarkers (SPECT scan, FDG PET scan, CSF, or amyloid scan). Twenty-one HC were recruited from the Alzheimer’s Disease Research Center at Columbia University. Assessments entail annual neurological and neuropsychological testing (Unified Data Set 3). They were evaluated for at least 2 consecutive years with a normal neuropsychological testing. The neuropsychological testing includes MMSE, MoCA, digit forward and backward, trail making A and B, fluency (phonemic and semantic), multilingual naming test, logical memory (CRAFT), selective reminding test, Benson complex figure (copy and recall), and Rosen, as well as global deficit score and Neuropsychiatric Inventory questionnaire. Five HC were recruited based on a negative amyloid scan and a more limited neuropsychological testing.
The AD cohort recruited by Precision Med were diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria36 by a neurologist or internist. In addition, the subjects underwent MRI/CT scans to rule out other causes of cognitive decline. Their MMSE score is ≤28. They exhibit deficits in two or more areas of cognition and have progressive worsening of memory and other cognitive functions including progressive deterioration of specific cognitive functions such as language (aphasia), motor skills (apraxia), and perceptions (agnosia). The diagnosis is further supported by impaired activities of daily living, altered patterns of behavior, and family history of similar disorders. The HC are self-reported without evidence for decline in cognitive functions. The HC have an MMSE of ≥29.
Peptides were synthesized by A&A, LLC (San Diego, CA) as purified material (>95% by reverse-phase HPLC). Peptides were fifteen 15-mers previously described as T cell epitopes9, which were combined into two α-syn peptide pools, one for the case study (n = 12) and one for the cross-sectional study (n = 11; Supplementary Table 2). Peptides were aliquoted in small volumes and stored at −20 °C to avoid multiple freeze–thaw cycles.
PBMC isolation and in vitro expansion
Venous blood was collected in anticoagulant (e.g., heparin or EDTA)-containing blood bags or tubes. PBMC were purified from whole blood using Ficoll-PaqueTM density-gradient centrifugation, according to the manufacturer’s instructions (GE Healthcare Bio-Sciences, Pittsburgh, PA). Cells were cryopreserved in liquid nitrogen suspended in FBS containing 10% (vol/vol) DMSO. For in vitro expansion, cryopreserved PBMCs were thawed in RPMI supplemented with 5% human serum (Gemini Bio-Products, West Sacramento, CA), 1% Glutamax (Gibco, Waltham, MA), 1% penicillin/streptomycin (Omega Scientific, Tarzana, CA), and 50 U/ml Benzonase (Millipore Sigma, Burlington, MA). The cells were then washed and viability was evaluated using the trypan blue dye exclusion method. Briefly, at a density of 2 × 106 per mL, the cells were plated in each well of a 24-well plate in the presence of a α-syn peptide pool at a concentration of 5 μg/ml and were incubated in a 37 °C humidified CO2 incubator for 2 weeks. Intermittently, every 3 days, cells were supplied with 10 U/ml recombinant human IL-2.
After 14 days of culture with α-synuclein peptide pool (5 μg/ml), α-synuclein-specific cellular responses were measured by IFNγ, IL-5, and IL-10 Fluorospot assay with all antibodies and reagents from Mabtech (Nacka Strand, Sweden). Plates were coated overnight at 4 °C with an antibody mixture containing mouse anti-human IFNγ (clone 1-D1K), mouse anti-human IL-5 (clone TRFK5), and mouse anti-human IL-10 (clone 9D7). Briefly, 1 × 105 cells were added to each well of pre-coated Immobilon-FL PVDF 96-well plates (Mabtech) in the presence of a 5 μg/ml peptide pool and incubated at 37 °C in a humidified CO2 incubator for 20–24 h. Cells from the in vitro culture stimulated with DMSO (corresponding to the percent DMSO in the peptide pool tests) were used to assess nonspecific/background cytokine production and PHA stimulation at 10 μg/ml was used as a positive control. All conditions were tested in triplicate. Fluorospot plates were developed according to the manufacturer’s instructions (Mabtech). Briefly, cells were removed and plates were washed six times with 200 μl PBS/0.05% Tween 20 using an automated plate washer. After washing, 100 μl antibody mixture containing IFNγ (7-B6-1-FS-BAM), IL-5 (5A10-WASP), and IL-10 (12G8-biotin) prepared in PBS with 0.1% BSA was added to each well and the plates were incubated for 2 h. The plates were again washed six times with 200 μl PBS/0.05% Tween 20 using an automated plate washer and incubated with diluted fluorophores (anti-BAM-490, anti-WASP-640, and SA-550) for 1 h at room temperature. Finally, the plates were once more washed six times with 200 μl PBS/0.05% Tween 20 using an automated plate washer and incubated with a fluorescence enhancer for 15 min at room temperature. The plates were blotted dry and spots were counted by computer-assisted image analysis (AID iSpot, Aid Diagnostica GMBH, Strassberg, Germany). Responses were considered positive if the net spot-forming cells (SFC) per 106 PBMC were ≥100, the stimulation index ≥2, and p ≤ 0.05 by Student’s t test or Poisson distribution test.
Intracellular cytokine staining (ICS)
After 14 days of culture, an intracellular cytokine staining (ICS) assay was performed by stimulating PBMCs with 5 μg/ml α-synuclein epitope pool for 2 h in complete RPMI medium at 37 °C. After 2 h, brefeldin A and monensin, each at a concentration of 2.5 μg/ml, were added for an additional 4 h. Cells were incubated for a total of 6 h at 37 °C in humidified CO2 incubator. Stimulated cells were harvested, washed, and stained for cell surface antigens according to the staining panel used (Supplementary Table 3), and fixable viability dye eFluor 506 (eBiosciences, Waltham, MA). After 30 min of staining, cells were washed, fixed using 4% paraformaldehyde and permeabilized using saponin buffer. Cells were stained for cytokines (Supplementary Table 3) in saponin buffer containing 10% FBS. Samples were acquired on a BD LSR II flow cytometer (BD Biosciences, San Jose, CA). Frequencies of CD3+ T cells responding to α-synuclein epitope pool were quantified by determining the total number of gated CD3+ and cytokine+ cells and background values subtracted (as determined from the medium alone control) using FlowJo X Software (FlowJo LLC, Ashland, OR). Combinations of cytokine producing cells were determined using Boolean gating. The gating strategy is described in Supplementary Fig. 5.
Participants were HLA typed by an ASHI-accredited laboratory at Murdoch University (Institute for Immunology & Infectious Diseases, Western Australia). HLA typing for class I (HLA A; B; C) and class II (DQA1; DQB1, DRB1 3,4,5; DPB1) was performed using locus-specific PCR amplification of genomic DNA. Primers used for amplification employed patient-specific barcoded primers. Amplified products were quantitated and pooled by subject, and up to 48 subjects were pooled. An indexed (eight indexed MiSeq runs) library was then quantitated using Kappa universal QPCR library quantification kits. Sequencing was performed using an Illumina MiSeq using 2 × 300 paired-end chemistry. Reads were quality-filtered and passed through a proprietary allele calling algorithm and analysis pipeline using the latest IMGT HLA allele database as a reference. The algorithm was developed by E.P. and S.M. and relies on periodically updated versions of the freely available international immunogenetics information system (http://www.imgt.org) and an ASHI-accredited HLA allele caller software pipeline, IIID HLA Analysis suite (http://www.iiid.com.au/laboratory-testing/). HLA association odds ratios and relative frequencies were calculated using the RATE program37 available from www.iedb.org.
Statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software, San Diego, CA). Data were analyzed using nonparametric statistical tests (Spearman test) because the data are not normally distributed. Fisher’s exact t test (two-tailed), which provides exact p values for the analysis of contingency tables, was calculated using online GraphPad tool Quickcalcs. Mann–Whitney test (two-tailed) was performed to compare gender-based distribution of PD and frequency of T cell responses in PD and age-matched healthy controls. For all analyses, differences were considered significant if the p value was ≤0.05.
Unless indicated in the figure legend (Fig. 1e, f), each donor sample was included in one experiment.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
All data generated or analyzed during this study are included in this article and its Supplementary Information. For HLA-typing information from the freely available international immunogenetics information system (http://www.imgt.org), and an ASHI-accredited HLA allele caller software pipeline, IIID HLA Analysis suite (http://www.iiid.com.au/laboratory-testing/) was used.
Postuma, R. B. & Berg, D. Advances in markers of prodromal Parkinson disease. Nat. Rev. Neurol. 12, 622–634 (2016).
Fahn, S. & Sulzer, D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1, 139–154 (2004).
Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136, 2419–2431 (2013).
Pilotto, A. et al. Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov. Disord. 32, 1025–1034 (2017).
Sulzer, D. & Surmeier, D. J. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov. Disord. 28, 41–50 (2013).
Sulzer, D. et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Parkinsons Dis. 4, 11 (2018).
Cebrian, C., Loike, J. D. & Sulzer, D. Neuroinflammation in Parkinson’s disease animal models: a cell stress response or a step in neurodegeneration? Curr. Top. Behav. Neurosci. 22, 237–270 (2015).
Cebrian, C., Loike, J. D. & Sulzer, D. Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkinson’s and other brain diseases. Front Neuroanat. 8, 114 (2014).
Sulzer, D. et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature 546, 656–661 (2017).
Pugliese, A. Autoreactive T cells in type 1 diabetes. J. Clin. Investig. 127, 2881–2891 (2017).
Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).
Ramaker, C., Marinus, J., Stiggelbout, A. M. & Van Hilten, B. J. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov. Disord. 17, 867–876 (2002).
Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010).
Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. Proc. Biol. Sci. 282, 20143085 (2015).
Wu, W. Y. et al. Hepatitis C virus infection: a risk factor for Parkinson’s disease. J. Viral Hepat. 22, 784–791 (2015).
Kim, J. M. et al. Association between hepatitis C virus infection and Parkinson’s disease. Mov. Disord. 31, 1584–1585 (2016).
Cheng, Y. & Newell, E. W. Deep profiling human T cell heterogeneity by mass cytometry. Adv. Immunol. 131, 101–134 (2016).
Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who’s who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43, 2797–2809 (2013).
Zhao, H., Liao, X. & Kang, Y. Tregs: where we are and what comes next? Front Immunol. 8, 1578 (2017).
Gendelman, H. E. et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis. 3, 10 (2017).
George, S. & Brundin, P. Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J. Parkinsons Dis. 5, 413–424 (2015).
Weihofen, A. et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol. Dis. 124, 276–288 (2019).
Hollenbach, J. A. et al. A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson’s disease. Proc. Natl Acad. Sci. USA 116, 7419–7424 (2019).
Van Den Eeden, S. K. et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157, 1015–1022 (2003).
Maletto, B., Gruppi, A. & Pistoresi-Palencia, M. C. Aging: the cellular immune response against autologous and foreign antigens is affected before the humoral response. Immunol. Lett. 40, 243–250 (1994).
Pfleger, C., Meierhoff, G., Kolb, H. & Schloot, N. C. Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J. Autoimmun. 34, 127–135 (2010).
Hemmer, B., Kerschensteiner, M. & Korn, T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 14, 406–419 (2015).
Pilli, D., Zou, A., Tea, F., Dale, R. C. & Brilot, F. Expanding role of T cells in human autoimmune diseases of the central nervous system. Front Immunol. 8, 652 (2017).
Marek, K. et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 82, 1791–1797 (2014).
Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566–576 (2016).
Lodygin, D. et al. beta-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. Nature 566, 503–508 (2019).
Latorre, D. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562, 63–68 (2018).
Lindestam Arlehamn, C. S. et al. Widespread Tau-specific CD4 T cell reactivity in the general population. J. Immunol. 10.4049/jimmunol.1801506 (2019).
Peter, I. et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939–946 (2018).
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011).
McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944 (1984).
Paul, S. et al. A population response analysis approach to assign Class II HLA-Epitope restrictions. J. Immunol. 194, 6164–6176 (2015).
We would like to thank the case study, PD patients, and other participants for donating samples to this study. We would also like to thank Dr. Stephen Grill at the Parkinson’s and Movement Disorders Center of Maryland for providing clinical information for the case study. We are also grateful to the La Jolla Institute for Immunology Clinical Studies Group and Flow Cytometry Core. This study was supported by NIH NINDS R01NS095435 (A.S., D.S.), P50NS108675 (D.G.S., A.W.A.), NIH NIA P50AG08702 (ADRC CUMC), the Parkinson’s Foundation (A.S., D.S.), the Michael J. Fox (A.S., D.S.), JPB (D.S.) and William F. Richter (D.S.) Foundations and UCSD-LJI Program in Immunology funding (A.S.)
The authors declare no competing interests.
Peer review information Nature Communications thanks Andreia D. Magalhães, Andrew West and the other anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lindestam Arlehamn, C.S., Dhanwani, R., Pham, J. et al. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun 11, 1875 (2020). https://doi.org/10.1038/s41467-020-15626-w
This article is cited by
Cell & Bioscience (2023)
npj Parkinson's Disease (2023)
Signal Transduction and Targeted Therapy (2023)
Cell Death Discovery (2023)
Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD
npj Parkinson's Disease (2023)